Month: September 2023

Ghent, 14 September 2023 – 6:30 p.m. – Press Release/Regulatory Information Highlights first half of 2023ABO-Group continues on its growth path and sees its total sales rise by another 10% to 40.4 million euros, amongst others due to strong organic growth of 14% in Belgium and the integration of the recent acquisitions of SEGED and DynaOpt in France Operating margins and net result were under pressure due to challenging (construction) market conditions in both France and the Netherlands, as well as the impact of rising interest rates Robust debt and solvency ratios provide a strong basis for further expansion of the acitvitiesOutlookWell-filled order book for the second half of the year – further development of the European mining sector expected to support geotechnical activities Integration of the two French and two Belgian acquisitions...

    Spineway organizes an international masterclasswith expert spine surgeons Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1 (Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses. The event featured some 20 scientific papers and interactive round-table discussions led by opinion-leading surgeons who discussed their respective working practices and philosophies, and their experience with the prostheses used around the world and available...

–   Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. The European Commission’s final decision on the Company’s Marketing Authorisation Application is expected within 67 days after the positive opinion. TransCon PTH is a prodrug of parathyroid hormone (PTH [1-34]) administered once daily. “We are pleased to...

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of strokeClinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024 Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028Paris, France, September 14, 2023 – 5.45 pm CEST – Acticor Biotech, (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its optimised development plan for Acute Ischemic Stroke (AIS) to register glenzocimab in Europe and the United States. ACTISAVE (NCT05070260) is an international phase 2/3 study, adaptive, multicentre, randomised, double-blind, placebo-controlled, parallel-group...

Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Capgemini launches its tenth Employee Share Ownership Plan Paris, September 14, 2023 – Capgemini announces the launch of its tenth Employee Share Ownership Plan (ESOP). This new employee share ownership plan is offered to approximately 97% of the employees and is part of the Group’s policy to associate all employees with its development and performance. This ESOP will be implemented through a capital increase reserved for the Capgemini employees for a maximum of 3,200,000 shares (i.e. 1.84% of outstanding shares), with settlement-delivery no later than December 19, 2023. As the 2018 ESOP reaches its term at the end of the year, this tenth plan will help maintain employee shareholding...

JCDecaux wins the contract for the City of Toulouse’s self-service bikes for 12 years, renewing its partnership that began in 2007 Paris, September 14th, 2023 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide and pioneer of self-service bikes, announces that it has won the contract for the self-service bikes in the City of Toulouse (the fourth-largest city in France) following a competitive tender. 50% of the new fleet will eventually comprise electric-assist bikes with onboard batteries that can be recharged at the stations. Supporting the development of eco-friendly mobility in ToulouseThis new 12-year contract will initially cover 400 stations – 117 more stations than today and 3,300 new bikes to meet the local authority’s expectations and the growing demand from people in Toulouse...